Alphatec Holdings, Inc 8-K, filed Sep 28, 2021
Alphatec Holdings, Inc. (ATEC)
About this 8-K
Alphatec Holdings, Inc filed this 8-K on September 28, 2021.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer Identification |
|
|
|
|
(Address of Registrant's Principal Executive Offices and Zip Code)
(
(Registrant's Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On September 28, 2021, Alphatec Holdings, Inc. (the “Company”) issued a press release providing a business update on its expected third quarter 2021 revenue results due to the impact of COVID-19.
A copy of the press release issued in connection with the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K.
This Current Report on Form 8-K and the related press release contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements. Forward-looking statements include but are not limited to: references to the Company’s revenue and growth outlook; planned product launches, introductions, regulatory submissions or clearances; efforts to transform sales and distribution channels; and the Company’s ability to compel surgeon adoption. Important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: uncertainty of success in developing new products or products currently in the pipeline; uncertainties in the Company’s ability to execute upon its strategic operating plan; failure to achieve acceptance of the Company’s products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval; continuation of favorable third party reimbursement; the Company’s ability to compete with other products or with emerging technologies; product liability exposure; an unsuccessful outcome in any litigation; claims related to the Company’s intellectual property; the Company’s ability to meet its financial obligations; and the impact of the COVID-19 pandemic on the Company and economy.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 104 |
|
Press Release, dated September 28, 2021 Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: September 28, 2021 |
ALPHATEC HOLDINGS, INC. |
||
|
|
|
||
|
|
By: |
|
/s/ J. Todd Koning |
|
|
Name: |
|
J. Todd Koning |
|
|
Its: |
|
Chief Financial Officer |
Exhibit 99.1
ATEC Provides Business Update
CARLSBAD, Calif., September 28, 2021 – Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, provided a business update today, ahead of investor meetings scheduled for the NASS 2021 meeting.
The resurgence of COVID-19 in the U.S. has pressured surgical procedure volumes in spine and affected hospital operations in the third quarter of 2021, with the impact persisting into the final month of the period. While procedure volume is recovering in some regions, overall, it has been lower than expected. Despite these impacts, ATEC expects U.S. spine revenue to grow over 25% year-over-year in the third quarter due to the continued strength of surgeon adoption and increasing sales force penetration; however, the Company now expects third quarter U.S. spine revenue to be down sequentially compared to the second quarter 2021. The integration of EOS imaging continues to be on track.
Pat Miles, Chairman and Chief Executive Officer, said, “Throughout the pandemic, ATEC has continued to relentlessly focus on stewarding better spine surgery through innovation. Our efforts have been rewarded with growth at rates well in excess of the overall spine industry, but we are not immune to the unpredictable market backdrop. We remain committed to setting the standard in spine surgery, and will continue to confidently navigate this dynamic environment.”
ATEC will showcase its comprehensive portfolio of innovative spine solutions and partner with renowned spine surgeons to demonstrate the clinical utility of the PTP technique and EOS imaging technology at the 2021 NASS meeting, which will be held at the Boston Convention and Exhibition Center this week.
About ATEC
ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC's Organic Innovation MachineTM is focused on developing new approaches that integrate seamlessly with the Company’s expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC's vision is to become the Standard Bearer in Spine. For more information, visit us at www.atecspine.com
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements. Forward-looking statements include but are not limited to: references to the Company’s revenue and growth outlook; planned product launches, introductions, regulatory submissions or clearances; efforts to transform sales and distribution channels; and the Company’s ability to compel surgeon adoption. Important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: uncertainty of success in developing new products or products currently in the pipeline; uncertainties in the Company’s ability to execute upon its strategic operating plan; failure to achieve acceptance of the Company’s products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval; continuation of favorable third party reimbursement; the Company’s ability to compete with other products or with emerging technologies; product liability exposure; an unsuccessful outcome in any litigation; claims related to the Company’s intellectual property; the Company’s ability to meet its financial obligations; and the impact of the COVID-19 pandemic on the Company and economy.
A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.
Investor/Media Contact:
Tina Jacobsen, CFA
Investor Relations
(760) 494-6790
investorrelations@atecspine.com
Company Contact:
J. Todd Koning
Chief Financial Officer
Alphatec Holdings, Inc.
investorrelations@atecspine.com